Owkin
- hard tech
- biotechnology
- horizon europe
- analytics
- core ai
- eit ecosystem
- oncology
- verified unicorns and $1b exits
- observatoire deeptech
- generative ai
- eit health
- drug development
- biotech, medtech and e-health
- genai applications
- techbio
- tech for biotech & pharma
- physician support tools
- ai drug discovery
- comparison
- digital pharma
- techbio drug discovery
- privacy protection
- precision medicine
- ai model layer
- participations bpifrance
- genai model maker
- modeling
- clinical trials
- medical research
- radiology
- novel ai
- compbio
- pathology
- privacy-enhancing technologies
- gold track (eit health)
- gold track 2021 (eit health)
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|
Revenues | 1.1m | 3.5m | 6.6m | 9.2m |
% growth | - | 229 % | 88 % | 40 % |
Profit | <1m | 1.2m | <1m | 1.6m |
% profit margin | 10 % | 34 % | 9 % | 17 % |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$2.1m | Seed | ||
* | $11.0m | Series A | |
€4.2m | Series A | ||
N/A | Series A | ||
* | €13.0m | Early VC | |
* | $25.0m | Series A | |
$18.0m Valuation: $125m 17.2x EV/LTM Revenues | Series A | ||
N/A | Grant | ||
* | $180m Valuation: $1.0b 98.5x EV/LTM Revenues | Growth Equity VC | |
* | $80.0m Valuation: $1.0b | Series B | |
Total Funding | €305m |
Related Content
Recent News about Owkin
EditOwkin is a pioneering company in the healthcare and biotechnology sector, specializing in AI-powered diagnostics and drug development. The company leverages advanced machine learning and biological insights to streamline and de-risk clinical trials, thereby accelerating the drug development process. Owkin serves a diverse clientele, including leading biopharma companies and top academic centers, by providing AI-driven solutions that integrate seamlessly into digital pathology workflows for accurate and timely diagnosis. The company operates in the global healthcare market, focusing on oncology and other critical disease areas. Owkin's business model revolves around partnerships and collaborations, offering bespoke AI models and multimodal patient data to enhance clinical trial recruitment and outcomes. Revenue is generated through strategic alliances, research collaborations, and the provision of AI diagnostics and data services.
Keywords: AI diagnostics, drug development, clinical trials, digital pathology, machine learning, oncology, biopharma, multimodal data, precision medicine, healthcare innovation.